作者:Darin J. Gustin、Yihong Li、Matthew L. Brown、Xiaoshan Min、Mike J. Schmitt、Malgorzata Wanska、Xiaodong Wang、Richard Connors、Sheere Johnstone、Mario Cardozo、Alan C. Cheng、Shawn Jeffries、Brendon Franks、Shyun Li、Shanling Shen、Mariwil Wong、Holger Wesche、Guifen Xu、Timothy J. Carlson、Matthew Plant、Kurt Morgenstern、Karen Rex、Joanna Schmitt、Angela Coxon、Nigel Walker、Frank Kayser、Zhulun Wang
DOI:10.1016/j.bmcl.2013.06.030
日期:2013.8
inhibition of both isoforms is likely required to block SphK dependent angiogenesis. A structure based approach was used to design and synthesize a series of SphK inhibitors resulting in the identification of the first potent inhibitors of both isoforms of human SphK. Additionally, to our knowledge, this series of inhibitors contains the only sufficiently potent inhibitors of murine SphK1 with suitable
鞘氨醇-1-磷酸(S1P)信号在有丝分裂,细胞迁移和血管生成中起着至关重要的作用。鞘氨醇激酶(SphKs)催化鞘磷脂代谢中的关键步骤,从而导致S1P的产生。SphK有两种同工型,对SphK缺陷小鼠的观察表明,这两种同工型可以弥补彼此的损失。因此,可能需要抑制两种同工型才能阻断SphK依赖性血管生成。基于结构的方法用于设计和合成一系列SphK抑制剂,从而鉴定出人类SphK两种同工型的第一种有效抑制剂。此外,据我们所知,